Xarelto is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1]. Bayer AG is also involved in the marketing and distribution of Xarelto in various regions [2].
What are the main uses for Xarelto?
Xarelto (rivaroxaban) is a medication used to prevent blood clots in several situations. It is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [3]. Additionally, Xarelto is indicated for the prophylaxis of DVT, which may lead to PE, in patients who have undergone hip or knee replacement surgery [3].
How does Xarelto work?
Xarelto is an anticoagulant, commonly referred to as a blood thinner. It works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade [4]. By blocking Factor Xa, Xarelto effectively reduces thrombin generation and the formation of blood clots [4].
When does Xarelto's patent expire?
The patent landscape for Xarelto is complex, with multiple patents covering different aspects of the drug, including composition, formulation, and methods of use. According to DrugPatentWatch.com, the earliest key patents for Xarelto have already expired [5]. However, other patents and regulatory exclusivities may still be in effect, influencing the availability of generic versions [5].
Who are Xarelto's main competitors?
Xarelto competes with other direct oral anticoagulants (DOACs) and older anticoagulant medications. Key competitors in the DOAC class include Eliquis (apixaban), manufactured by Bristol Myers Squibb and Pfizer, and Pradaxa (dabigatran), made by Boehringer Ingelheim [6]. Warfarin, a vitamin K antagonist, is another established competitor, though it requires more frequent monitoring [7].
What are the risks associated with Xarelto?
The primary risk associated with Xarelto, like other anticoagulants, is bleeding [3]. This can range from minor bruising to severe, life-threatening hemorrhage. Patients taking Xarelto are advised to seek immediate medical attention if they experience symptoms of excessive bleeding, such as unusual bruising, nosebleeds that don't stop, blood in urine or stool, or heavy menstrual bleeding [3].
Are there generic versions of Xarelto available?
The availability of generic versions of Xarelto is influenced by patent expirations and any ongoing legal challenges. As of recent information, generic versions of rivaroxaban are becoming available as primary patents have expired [5]. The exact timing and market entry of generics can vary by region due to differing patent laws and regulatory processes.
What is the cost of Xarelto?
The cost of Xarelto can vary significantly depending on factors such as insurance coverage, pharmacy, dosage, and whether a generic version is available. Without insurance, Xarelto can be expensive, with prices often running into hundreds of dollars per month. Generic rivaroxaban is generally less expensive than the brand-name drug. Patient assistance programs may be available from the manufacturer for eligible individuals [8].
What clinical data supports Xarelto's use?
Xarelto's efficacy and safety have been established through numerous clinical trials. Landmark studies such as ROCKET AF (for atrial fibrillation) and EINSTEIN (for DVT and PE) have demonstrated its effectiveness in preventing thrombotic events and its favorable safety profile compared to older anticoagulants like warfarin [9][10]. These trials form the basis for Xarelto's approvals in various indications.
Sources:
[1] https://www.janssen.com/
[2] https://www.bayer.com/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202174s037,204100s008,205041s005,205101s004lbl.pdf
[4] https://www.drugbank.ca/drugs/Xarelto
[5] https://www.drugpatentwatch.com/
[6] https://www.bmj.com/content/369/bmj.m1476
[7] https://www.mayoclinic.org/diseases-conditions/deep-vein-thrombosis/diagnosis-treatment/drc-20352557
[8] https://www.goodrx.com/xarelto
[9] https://www.nejm.org/doi/full/10.1056/NEJMoa1009044
[10] https://www.nejm.org/doi/full/10.1056/NEJMoa1107438